Clinical Trial Update: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy [NA]

View source ↗

Summary

Clinical trial update for fosaprepitant dimeglumine evaluating prevention of nausea and vomiting in gastrointestinal cancer patients receiving combination chemo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Nausea and Vomiting Associated with Chemotherapy

Drugs mentioned

• fosaprepitant dimeglumine (fosaprepitant dimeglumine)

Snippet

Sponsor: Philip Philip | Conditions: Gastrointestinal Cancer, Nausea Post Chemotherapy | NA | Status: COMPLETED | Results posted: 2020-10-20